JP5024635B2 - 睡眠覚醒障害の治療 - Google Patents

睡眠覚醒障害の治療 Download PDF

Info

Publication number
JP5024635B2
JP5024635B2 JP2008515949A JP2008515949A JP5024635B2 JP 5024635 B2 JP5024635 B2 JP 5024635B2 JP 2008515949 A JP2008515949 A JP 2008515949A JP 2008515949 A JP2008515949 A JP 2008515949A JP 5024635 B2 JP5024635 B2 JP 5024635B2
Authority
JP
Japan
Prior art keywords
sleep
formula
optical isomer
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2008515949A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545795A (ja
Inventor
アブダラー アーナオウ
ウィルヘルムス エッチ．アイ．エム． ドリンケンバーグ
ジョセフ パルンボ
ジョナサン スポーン
Original Assignee
エスケー バイオファーマスティカルズ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37085728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5024635(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エスケー バイオファーマスティカルズ カンパニー リミテッド filed Critical エスケー バイオファーマスティカルズ カンパニー リミテッド
Publication of JP2008545795A publication Critical patent/JP2008545795A/ja
Application granted granted Critical
Publication of JP5024635B2 publication Critical patent/JP5024635B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008515949A 2005-06-08 2006-06-07 睡眠覚醒障害の治療 Expired - Lifetime JP5024635B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68863805P 2005-06-08 2005-06-08
US60/688,638 2005-06-08
PCT/US2006/022407 WO2006133393A1 (en) 2005-06-08 2006-06-07 Treatment of sleep-wake disorders

Publications (2)

Publication Number Publication Date
JP2008545795A JP2008545795A (ja) 2008-12-18
JP5024635B2 true JP5024635B2 (ja) 2012-09-12

Family

ID=37085728

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008515949A Expired - Lifetime JP5024635B2 (ja) 2005-06-08 2006-06-07 睡眠覚醒障害の治療

Country Status (17)

Country Link
US (8) US8440715B2 (enExample)
EP (1) EP1890684B1 (enExample)
JP (1) JP5024635B2 (enExample)
KR (1) KR101335941B1 (enExample)
CN (1) CN101217949B (enExample)
AU (1) AU2006254899B2 (enExample)
BE (1) BE2020C004I2 (enExample)
BR (1) BRPI0613697A2 (enExample)
CA (1) CA2611713C (enExample)
DK (1) DK1890684T3 (enExample)
ES (1) ES2435403T3 (enExample)
FR (1) FR20C1014I2 (enExample)
NL (1) NL301037I2 (enExample)
PL (1) PL1890684T3 (enExample)
RU (1) RU2417077C2 (enExample)
TW (2) TW201328689A (enExample)
WO (1) WO2006133393A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1890684T3 (pl) 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
US8552060B2 (en) * 2005-06-22 2013-10-08 Sk Biopharmaceuticals Co., Ltd. Methods for treatment of sexual dysfunction
AU2010270971B2 (en) * 2009-06-22 2015-08-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
ES2447295T3 (es) 2009-11-06 2014-03-11 Sk Biopharmaceuticals Co., Ltd. Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) * 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
RU2019114940A (ru) * 2013-03-13 2019-06-28 ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи Лечение катаплексии
DK3021838T3 (da) 2013-07-18 2020-08-24 Jazz Pharmaceuticals Ireland Ltd Behandling af fedme
TWI655179B (zh) 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
JP6466792B2 (ja) * 2015-07-03 2019-02-06 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
TWI637765B (zh) * 2016-05-10 2018-10-11 台灣共振波研發股份有限公司 Soothing device for attention deficit hyperactivity disorder
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
CN121202730A (zh) 2016-09-06 2025-12-26 爱尔兰贾兹制药有限公司 (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的制备方法、其组合物及用途
JP7074750B2 (ja) 2016-10-06 2022-05-24 ジャズ ファーマスティカルズ アイルランド リミテッド カルバモイルフェニルアラニノール化合物およびその使用
KR20200016889A (ko) 2017-06-02 2020-02-17 재즈 파마슈티칼즈 아일랜드 리미티드 과다 졸림증을 치료하기 위한 방법 및 조성물
SG11202000817SA (en) * 2017-07-31 2020-02-27 Jazz Pharmaceuticals Ireland Ltd Carbamoyl phenylalaninol analogs and uses thereof
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
US11033214B1 (en) * 2020-05-19 2021-06-15 United Arab Emirates University Wearable eye tracking system
KR102390194B1 (ko) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
WO2024102718A1 (en) * 2022-11-07 2024-05-16 Axsome Therapeutics Compositions and methods for treating insomnia
US20260199282A1 (en) * 2022-11-30 2026-07-16 Axsome Therapeutics, Inc. Methods and compositions for improving driving performance
CN121620365A (zh) 2023-06-29 2026-03-06 艾克萨姆治疗股份有限公司 向哺乳期妇女施用索安非托的方法
AU2025216819A1 (en) * 2024-01-29 2026-07-09 Axsome Therapeutics, Inc. Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder
WO2026125068A1 (en) 2024-12-10 2026-06-18 Noucor Health, S.A. Process to obtain solriamfetol hydrochloride

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939660A1 (de) * 1979-09-29 1981-04-16 Basf Ag, 6700 Ludwigshafen Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) * 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) * 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
CA2240060C (en) * 1996-10-10 2007-07-17 Sk Corporation O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
HUP0303243A3 (en) * 2001-02-27 2012-07-30 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing and treating bipolar disorder
MXPA03007720A (es) * 2001-02-27 2004-11-12 Johnson & Johnson Compuestos de carbamato para su uso en la prevencion o el tratamiento de transtornos de ansiedad.
RS50676B (sr) * 2001-02-27 2010-06-30 Ortho-Mcneil Pharmaceutical Inc. Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
RU2007119648A (ru) 2004-10-28 2008-12-10 СК Холдингз Ко. Способ лечения депрессии
PL1890684T3 (pl) * 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
US8552060B2 (en) 2005-06-22 2013-10-08 Sk Biopharmaceuticals Co., Ltd. Methods for treatment of sexual dysfunction
EP1928451B1 (en) 2005-07-26 2011-12-28 SK Biopharmaceuticals Co., LTD Methods for treating substance-related disorders
AU2007313017A1 (en) 2006-10-13 2008-04-24 Janssen Pharmaceutica, N.V. Phenylalkylamino carbamate compositions
AU2010270971B2 (en) 2009-06-22 2015-08-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
ES2447295T3 (es) 2009-11-06 2014-03-11 Sk Biopharmaceuticals Co., Ltd. Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
KR102005483B1 (ko) 2012-10-19 2019-07-31 삼성디스플레이 주식회사 박막 트랜지스터 기판 및 그의 수리 방법
RU2019114940A (ru) * 2013-03-13 2019-06-28 ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи Лечение катаплексии

Also Published As

Publication number Publication date
RU2008100019A (ru) 2009-07-20
TWI419681B (zh) 2013-12-21
PL1890684T3 (pl) 2014-05-30
FR20C1014I1 (enExample) 2020-06-12
US20210078943A1 (en) 2021-03-18
BE2020C004I2 (enExample) 2026-01-06
US10351517B2 (en) 2019-07-16
EP1890684B1 (en) 2013-08-14
WO2006133393A1 (en) 2006-12-14
CN101217949A (zh) 2008-07-09
CN101217949B (zh) 2012-10-17
US12209059B2 (en) 2025-01-28
US11753368B2 (en) 2023-09-12
US20140350098A1 (en) 2014-11-27
EP1890684A1 (en) 2008-02-27
KR101335941B1 (ko) 2013-12-04
AU2006254899A1 (en) 2006-12-14
RU2417077C2 (ru) 2011-04-27
TW201328689A (zh) 2013-07-16
FR20C1014I2 (fr) 2021-04-23
US20130137764A1 (en) 2013-05-30
US20170158622A1 (en) 2017-06-08
US20250109099A1 (en) 2025-04-03
US20240239740A1 (en) 2024-07-18
US9604917B2 (en) 2017-03-28
CA2611713C (en) 2013-10-01
ES2435403T3 (es) 2013-12-19
US8440715B2 (en) 2013-05-14
NL301037I2 (nl) 2020-05-12
US8877806B2 (en) 2014-11-04
US20090312416A1 (en) 2009-12-17
KR20080035565A (ko) 2008-04-23
US20190367448A1 (en) 2019-12-05
BRPI0613697A2 (pt) 2011-01-25
JP2008545795A (ja) 2008-12-18
NL301037I1 (enExample) 2020-04-01
CA2611713A1 (en) 2006-12-14
TW200716084A (en) 2007-05-01
AU2006254899B2 (en) 2011-11-24
DK1890684T3 (da) 2013-10-14

Similar Documents

Publication Publication Date Title
US12209059B2 (en) Treatment of sleep-wake disorders
JP5921539B2 (ja) 下肢静止不能症候群を治療する方法
JP5901528B2 (ja) 線維筋痛症候群の治療方法
JP2004527492A (ja) 運動障害の予防もしくは治療における使用のためのカルバメート化合物
JP5271473B2 (ja) 神経障害性疼痛ならびに群発性頭痛および偏頭痛に関連する疼痛の予防もしくは治療における使用のためのカルバメート化合物
US6462089B1 (en) Method for correcting the vigilance disorders associated with myopathies
US20200197365A1 (en) Treatment with nmda receptor modulators
JP2024522632A (ja) 自閉症スペクトラム障害（ａｓｄ）を治療する方法
JP4362367B2 (ja) 神経因性疼痛および群発および偏頭痛に伴う疼痛の防止または処置に使用するためのカルバメート化合物
JP4362368B2 (ja) 神経因性疼痛および群発および偏頭痛に伴う疼痛の防止または処置に使用するためのカルバメート化合物

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120201

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20120221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120523

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120606

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150629

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5024635

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250